Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) generates frequent news flow around its work in hereditary angioedema (HAE) and the commercialization of EKTERLY (sebetralstat). Company press releases highlight regulatory approvals, commercial launches, clinical data presentations and financial updates tied to this first and only oral on-demand treatment for acute HAE attacks in people 12 years of age and older.
News items cover major milestones such as FDA approval of EKTERLY in the United States, subsequent approvals in the European Union, United Kingdom, Switzerland, Australia, Singapore and Japan, and the initiation of commercial launches in the U.S. and Germany. KalVista also reports on licensing and commercialization agreements with partners like Kaken Pharmaceutical in Japan, Pendopharm in Canada and Multicare Pharmaceuticals in Latin America, which expand EKTERLY’s reach into additional markets.
Investors and clinicians following KALV can track updates on net product revenue from EKTERLY, patient start forms, prescriber activation and refill trends, as well as financing events such as the issuance of convertible senior notes. The company regularly announces new clinical and real‑world data from the KONFIDENT, KONFIDENT‑S and KONFIDENT‑KID studies, including patient satisfaction, pediatric interim results and European experience with sebetralstat, often presented at meetings such as the American College of Allergy, Asthma & Immunology Annual Scientific Meeting and the German Allergy Congress.
Additional KalVista news includes corporate governance developments, board and executive appointments, inducement equity grants and participation in healthcare investor conferences. This news page allows readers to follow how KalVista advances EKTERLY globally, engages with the HAE community and reports on its operational and financial progress over time.
KalVista Pharmaceuticals (NASDAQ: KALV) reported inducement option grants for a newly hired employee: an aggregate of 6,750 options granted on March 1, 2026, under Nasdaq Listing Rule 5635(c)(4). Exercise price will equal the first reported closing price after the grant. Options vest 25% after one year, then monthly over three years, have a 10-year term, and are governed by the company's Inducement Equity Incentive Plan and a stock option agreement.
KalVista (Nasdaq: KALV) reported new clinical data showing high patient satisfaction and shifting treatment behavior with oral EKTERLY (sebetralstat). In KONFIDENT-S, patients treated 2,464 attacks with sebetralstat; 83.1% of treated attacks rated satisfied or better and use of injectables fell with repeated use.
Analyses showed treating within 30 minutes predicted faster symptom relief, with simulations suggesting nearly 90% might experience relief within 12 hours.
KalVista Pharmaceuticals (Nasdaq: KALV) will present fireside chats at two investor conferences in March 2026. The company will speak at TD Cowen on March 4, 2026 at 11:10 a.m. EST and at Citizens Life Sciences on March 11, 2026 at 10:45 a.m. EST.
According to the company, live audio webcasts will be available on the Investors section of its website, with archived replays posted about two hours after each event.
KalVista (Nasdaq: KALV) said the new International Pediatric HAE Guideline recommends EKTERLY (sebetralstat) as a first-line on-demand therapy for acute hereditary angioedema attacks in adolescents aged 12 and older.
The guideline cites robust clinical evidence, notes EKTERLY is the first oral on-demand option for 12+, follows seven global approvals in 2025, and highlights ongoing pediatric development with an NDA for ages 2–11 on track for Q3 2026.
KalVista Pharmaceuticals (Nasdaq: KALV) announced the acceptance of three abstracts for presentation at the 2026 AAAAI Annual Meeting in Philadelphia, Feb 27–Mar 2, 2026. Two poster sessions are scheduled Friday, Feb 27 (2:45–3:45 pm ET) and one late-breaking poster on Sunday, Mar 1 (9:45–10:45 am ET).
Titles include placebo‑controlled response drivers, on‑demand treatment patterns from KONFIDENT‑S, and an investigator‑initiated ECRINS survey on attack management and burden. Links to presentations will be available on the company website under Publications.
KalVista Pharmaceuticals (Nasdaq: KALV) announced inducement option grants to six newly hired employees totaling 96,750 shares on February 1, 2026. Options vest 25% after one year, then monthly over three years, have a 10-year term, and an exercise price equal to the first reported closing price after the grant date.
Grants were made under KalVista’s Inducement Equity Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
KalVista (Nasdaq: KALV) reported preliminary unaudited global net product revenue for its oral on-demand HAE therapy EKTERLY (sebetralstat) of approximately $35 million in Q4 2025 and $49 million for full-year 2025 following a July 7 US launch.
Operational traction includes 1,318 patient start forms and 580 activated US prescribers through December 31, 2025, strong early uptake in Germany, regulatory approvals in seven markets, a new Latin America licensing deal with Multicare, and completion of Phase 3 KONFIDENT-KID pediatric enrollment with an expected pediatric NDA filing in Q3 2026.
KalVista Pharmaceuticals (Nasdaq: KALV) announced that Japan's Ministry of Health, Labor and Welfare granted marketing and manufacturing approval for EKTERLY (sebetralstat) as an oral on-demand treatment for acute hereditary angioedema (HAE) attacks in adults and adolescents aged 12 and older.
EKTERLY is the first and only oral on-demand HAE treatment approved in Japan and will be commercialized in Japan by partner Kaken Pharmaceutical, which plans to launch after EKTERLY is listed on the Japanese National Health Insurance system. Approval relied on the phase 3 KONFIDENT trial—the largest HAE study (136 patients, 66 sites, 20 countries)—with results published in the New England Journal of Medicine showing faster symptom relief, reduced attack severity, and attack resolution versus placebo. Since July 3, 2025, EKTERLY has received seven regulatory approvals across major markets.
KalVista Pharmaceuticals (Nasdaq: KALV) reported third-quarter 2025 results and an operational update focused on the commercial launch of EKTERLY. The company recognized $13.7M in net product revenue for Q3 and received 937 patient start forms through October with 423 unique prescribers activated. EKTERLY launched in Germany and received approvals in the EU, Switzerland and Australia. KalVista closed a $144M convertible note and held $309.2M in cash and marketable securities as of September 30, 2025.
R&D declined to $12.0M and SG&A rose to $46.5M in Q3 2025, reflecting commercialization activity.
KalVista (Nasdaq: KALV) presented new patient satisfaction and pediatric data for EKTERLY (sebetralstat) at ACAAI 2025 on November 6, 2025.
Key findings: in KONFIDENT-S, 1,089 attacks treated by patients who switched from injectable on-demand therapies had a median satisfaction score of 2 on a −3 to 3 Likert scale, with 84% of attacks rated satisfied/very/extremely satisfied. Interim KONFIDENT-KID results (as of June 6, 2025) in 26 children covering 65 attacks showed mean 0.8 attacks/month, median treatment administration time by caregiver/patient 30 minutes, median time to symptom relief in the 150 mg cohort 1.5 hours, and no serious or treatment-related adverse events reported.
Complementary Delphi and survey data highlighted barriers to injectable care (86% delay rate) and strong patient preference for oral on-demand treatment (89%).